Today: 16 April 2026
Regencell Bioscience (RGC) stock slid 8% into the New Year’s Day market shutdown — what’s next
1 January 2026
1 min read

Regencell Bioscience (RGC) stock slid 8% into the New Year’s Day market shutdown — what’s next

NEW YORK, January 1, 2026, 10:46 ET — Market closed.

  • Regencell Bioscience Holdings last closed down 8.3% at $21 on Dec. 31
  • The company’s investor updates show no new press release since Oct. 31
  • U.S. stocks are shut for New Year’s Day; macro data hits before trading resumes

Regencell Bioscience Holdings’ shares last closed down 8.3% at $21 on Wednesday, just before U.S. markets shut for the New Year’s Day holiday.

The latest swing underlined the stock’s extreme volatility: Nasdaq data show a 52-week range spanning roughly $0.09 to $83.60.

That matters now because the move came without an obvious company-specific catalyst in the past day, leaving traders to focus on liquidity and positioning into the first session after the holiday. The company’s investor-relations site lists its most recent press release as Oct. 31.

Trading was wide on the day. The stock ranged from $21.00 to $23.23 and closed at the low, with about 173,000 shares traded, market data show.

Volume ran below its recent average, a reminder that relatively small orders can move the stock sharply when participation is light. The shares also remain above key moving-average levels tracked by market technicians, which some traders use as a rough read on trend.

Regencell, based in Hong Kong, says it is developing Traditional Chinese Medicine (TCM) treatments — herbal-based therapies rooted in Chinese medical practice — for neurocognitive conditions including ADHD and autism spectrum disorder.

Market data trackers put Regencell’s equity value at roughly $10.4 billion, with about 494 million shares outstanding.

The company’s most recent annual report on Form 20-F — the SEC filing used by foreign private issuers — was filed on Oct. 31, SEC records show.

Regencell last year carried out a 38-for-1 forward stock split, which increases the number of shares while lowering the price per share, in a move it said required no action by shareholders.

Before trading resumes, investors will parse a fresh read on U.S. factory activity: the ISM manufacturing PMI, a survey-based gauge of manufacturing conditions, is due at 10 a.m. ET on Friday.

Construction spending data are also scheduled for 10 a.m. ET the same day, according to an economic calendar, and can move rates and the dollar — inputs that often ripple through equities.

Next week brings heavier macro catalysts, led by the U.S. jobs report for December on Jan. 9 and the consumer price index on Jan. 13, Labor Department schedules show.

Stock Market Today

  • Expand Energy (EXE) Shows Signs of Undervaluation Amid Share Price Drop
    April 16, 2026, 1:30 AM EDT. Expand Energy's stock fell 10.8% over the past month, closing at $96.05, raising questions about its valuation. Despite a 5.5% decline year-to-date, the company shows strong long-term gains, including 162.6% over five years. A Discounted Cash Flow (DCF) analysis estimates intrinsic value at $266.56 per share, suggesting the stock is roughly 64% undervalued. This model projects cash flow growth to 2035, accounting for risk and time value of money. Meanwhile, Expand Energy's current Price to Earnings (P/E) ratio is 12.69, below the Oil and Gas industry average, indicating potential undervaluation in market multiples as well. Investors are urged to consider these fundamentals amid recent price weakness to reassess the company's value.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 16.04.2026

16 April 2026
LIVEMarkets rolling coverageStarted: April 16, 2026, 12:00 AM EDTUpdated: April 16, 2026, 1:35 AM EDT Expand Energy (EXE) Shows Signs of Undervaluation Amid Share Price Drop April 16, 2026, 1:30 AM EDT. Expand Energy's stock fell 10.8% over the past month, closing at $96.05, raising questions about its valuation. Despite a 5.5% decline year-to-date, the company shows strong long-term gains, including 162.6% over five years. A Discounted Cash Flow (DCF) analysis estimates intrinsic value at $266.56 per share, suggesting the stock is roughly 64% undervalued. This model projects cash flow growth to 2035, accounting for risk and time value of
Norse Atlantic Cancels All LAX Summer Flights as Fuel Costs Force Los Angeles Retreat

Norse Atlantic Cancels All LAX Summer Flights as Fuel Costs Force Los Angeles Retreat

16 April 2026
Norse Atlantic Airways has canceled all planned summer flights from Los Angeles to London Gatwick, Paris, and Rome, citing surging jet fuel costs. The airline launched a $110 million rights issue, secured a $70 million bridge loan, and withdrew its 2026 outlook. Routes disappeared from booking systems on April 14. Norse had been the only scheduled operator on the Gatwick-Los Angeles route.
S&P 500 Hits Record High as Iran Deal Hopes, Bank Earnings Lift Wall Street

S&P 500 Hits Record High as Iran Deal Hopes, Bank Earnings Lift Wall Street

16 April 2026
The S&P 500 closed at a record 7,022.95 and the Nasdaq at 24,016.02 on Wednesday, erasing losses from the March selloff tied to the Feb. 28 conflict. Bank of America reported $8.6 billion in first-quarter net income, up 17%, while Morgan Stanley posted record revenue. Talks between Washington and Tehran raised hopes for easing oil supply fears, but Brent crude stayed elevated at $94.93 a barrel.
Tesla’s U.S. Solar Bet Faces China Export Threat as Energy Arm Becomes More Profitable Than Cars

Tesla’s U.S. Solar Bet Faces China Export Threat as Energy Arm Becomes More Profitable Than Cars

16 April 2026
China is considering export restrictions on advanced solar-manufacturing equipment to the U.S., potentially affecting Tesla’s plans for new factories, sources told Reuters. Tesla aims to buy $2.9 billion in solar-panel equipment from China and expand U.S. solar production. China produces over 80% of global solar panel components. No final decision has been made, and consultations remain preliminary.
Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

15 April 2026
Hims & Hers Health shares rose 14% to $24.29 after the FDA said it will review restrictions on several peptides, including BPC-157 and TB-500. The agency set a July advisory meeting and will remove some peptides from its safety-risk list within a week. Hims, which acquired a California peptide facility last year, reported $2.35 billion in 2025 revenue and 2.511 million subscribers.
ICL stock today: ICL Group ends 2025 up 3% as China potash contracts shape the 2026 view
Previous Story

ICL stock today: ICL Group ends 2025 up 3% as China potash contracts shape the 2026 view

Dow Jones today: Market closed for New Year after year-end dip; what Wall Street watches next
Next Story

Dow Jones today: Market closed for New Year after year-end dip; what Wall Street watches next

Go toTop